• Citer

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.

par Awada, Ahmad ;Hendlisz, Alain ;Gil, Thierry ;Bartholomeus, Sylvie;Mano, Max S.;de Valeriola, Dominique ;Strumberg, Dirk;Brendel, Erich;Haase, Claus G;Schwartz, Brian;Piccart-Gebhart, Martine
Référence British Journal of Cancer, 92, 10, page (1855-1861)
Publication Publié, 2005-05

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Auteur:	Awada, Ahmad; Hendlisz, Alain; Gil, Thierry; Bartholomeus, Sylvie; Mano, Max S.; de Valeriola, Dominique; Strumberg, Dirk; Brendel, Erich; Haase, Claus G; Schwartz, Brian; Piccart-Gebhart, Martine
Informations sur la publication:	British Journal of Cancer, 92, 10, page (1855-1861)
Statut de publication:	Publié, 2005-05
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	BAY 43-9006
	Efficacy
	Pharmacokinetics
	Safety
	Solid tumours
	Targeted agent
MeSH keywords:	Adult
	Aged
	Benzenesulfonates -- administration & dosage
	Benzenesulfonates -- adverse effects
	Benzenesulfonates -- pharmacokinetics
	Carcinoma, Renal Cell -- drug therapy
	Drug Administration Schedule
	Female
	Humans
	Kidney Neoplasms -- drug therapy
	Male
	Maximum Tolerated Dose
	Middle Aged
	Neoplasms -- drug therapy
	Pyridines -- administration & dosage
	Pyridines -- adverse effects
	Pyridines -- pharmacokinetics
Note générale:	Clinical Trial
	Clinical Trial, Phase I
	Journal Article
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0007-0920
	info:doi/10.1038/sj.bjc.6602584
	info:pii/6602584
	info:scp/20344362911
	info:pmid/15870716
	PMC2361774